At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 17 enrolled
Drug / intervention
RVT-1401 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension of RVT-1401 in Myasthenia Gravis Patients
In Brief
A Phase 2 clinical trial evaluating RVT-1401 and Placebo for Myasthenia Gravis. Completed, enrolled 17 participants across 20 sites in 2 countries.
Detailed Summary
The purpose of the current study is to assess safety/tolerability and key pharmacodynamic (PD) effects that are considered to be associated with clinical benefit (reduction of total IgG and anti-AChR-IgG) in Myasthenia Gravis patients following treatment with RVT-1401 (also known as IMVT-1401) compared to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyasthenia Gravis
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMar 2019
Enrollment StartMay 2019
Primary CompletionOct 2020
Study CompletionDec 2020
TodayJul 2026
First PostedMar 5, 2019
Enrollment StartMay 21, 2019
Primary CompletionOct 7, 2020
Study CompletionDec 21, 2020
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 7.3 years ago
Interventions
RVT-1401drug
Subcutaneous administration of RVT-1401
Placebodrug
Subcutaneous administration of Placebo